We first tested the responses of U87 and U251 glioma cell lines to the STAT3 degrader SD‐36 and Stattic using a 3‐day cell viability assay and found that the survival rate of these cell lines decreased more strongly with SD‐36 in general than Stattic treatment (Figure 1A). This evidence concerns the gene STAT3 and central nervous system cancer.